Screener
Amphastar Pharmaceuticals AMPH Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The source filing: Amphastar Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:41 PM EST
- Fiscal year
- FY2025
- Accession
- 0001297184-26-000009
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Deposits and other assets | (4,361) | (4,119) | 1,390 |
| Net cash used in investing activities | (70,332) | (124,930) | (649,116) |
| Cash Flows From Financing Activities: | |||
| Proceeds from equity plans, net of withholding tax payments | 2,855 | (4,849) | 10,974 |
| Purchase of treasury stock | (75,586) | (85,458) | (58,144) |
| Debt issuance costs | (687) | (816) | (25,079) |
| Proceeds from borrowing under lines of credit | 6,216 | 18,433 | — |
| Proceeds from issuance of long-term debt | — | — | 845,000 |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Amphastar Pharmaceuticals's stock issuance proceeds?
- Amphastar Pharmaceuticals (AMPH) reported stock issuance proceeds of $1.98M in Q4 2025.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Amphastar Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude